At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,508 enrolled
Drug / intervention
"augmented" CRRT regimenprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
In Brief
A Phase 4 clinical trial evaluating "augmented" CRRT regimen for Acute Renal Failure. Completed, enrolled 1,508 participants across 1 site.
Detailed Summary
This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Renal Failure
CountriesAustralia
CollaboratorsANZICS Clinical Trials Group
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2005
Enrollment StartNov 2005
Primary CompletionOct 2008
Study CompletionJan 2009
TodayJul 2026
First PostedSep 22, 2005
Enrollment StartNov 1, 2005
Primary CompletionOct 1, 2008
Study CompletionJan 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 20.8 years ago
Interventions
"augmented" CRRT regimenprocedure
We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.